SCHEMBL27403191

SCHEMBL27403191

CNc1cc(CN2CCOCC2)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 1/20 0.51
NPC1 O15118 1/20 0.51
TP53 P04637 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
SIGMAR1 Q99720 2/20 0.50
POLB P06746 2/20 0.50
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
LRRK2 Q5S007 1/20 0.47
CYP2A13 Q16696 2/20 0.47
NCF1 P14598 1/20 0.47
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
PDE4B Q07343 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25682600 0.84 HRH3 (0.51) HRH3SMN1; SMN2MEN1NPC1TP53
SCHEMBL5618352 0.82 SMN1; SMN2 (0.71) HRH3SMN1; SMN2MEN1NPC1TP53
SCHEMBL25682829 0.82 HRH3 (0.50) HRH3SMN1; SMN2NPC1TP53TSHR
SCHEMBL14320176 0.82 HRH3 (0.50) HRH3SMN1; SMN2MEN1NPC1TP53
SCHEMBL14872333 0.80 HRH3 (0.59) HRH3SMN1; SMN2MEN1NPC1TP53
SCHEMBL24289620 0.80 HRH3 (0.47) HRH3SMN1; SMN2MEN1NPC1TP53
SCHEMBL13161945 0.80 HRH3 (0.62) HRH3SMN1; SMN2MEN1NPC1TP53
SCHEMBL19241863 0.79 HRH3 (0.50) HRH3SMN1; SMN2NPC1TP53TSHR
SCHEMBL5095148 0.78 HRH3 (0.65) HRH3SMN1; SMN2MEN1NPC1RAB9A
SCHEMBL11948468 0.78 HRH3 (0.56) HRH3SMN1; SMN2MEN1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 HRH3 2996/4885SMN1; SMN2 2564/4885MEN1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.